skip to content
Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis : clinical effectiveness and harms Preview this item
ClosePreview this item
Checking...

Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis : clinical effectiveness and harms

Author: Kasandra Gauthier; Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa, Ontario : Canadian Agency for Drugs and Technologies in Health, February 2012.
Series: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
Edition/Format:   eBook : Document : National government publication : English
Summary:
Osteoporosis is a skeletal disorder characterized by compromised bone strength, predisposing patients to an increased risk of fracture. The postmenopausal form of osteoporosis affects more than 1.5 million Canadians, with prevalence increasing from 6% of women aged 50 to 59 years to more than 40% of women aged 80 years and older. Consequences of sustaining a fracture may be serious and include increased risk of  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Material Type: Document, Government publication, National government publication, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Kasandra Gauthier; Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 793582938
Notes: Title from PDF title page.
Description: 1 online resource (1 PDF file (41 pages)) : illustration.
Contents: Acronyms and abbreviations --
Executive summary --
1. Context and policy issues --
2. Research question --
3. Key message --
4. Methods --
5. Results --
6. Discussion --
7. Conclusions and implications for decision- or policy-making --
8. References --
Appendix 1: Literature search strategy --
Appendix 2: Selection of included studies --
Appendix 3: Summary of study characteristics of included studies --
Appendix 4: Summary of relevant patient population and baseline characteristics --
Appendix 5: Critical appraisal of individual studies.
Series Title: Rapid response report (Canadian Agency for Drugs and Technologies in Health)
Responsibility: Kasandra Gauthier, Annie Bai, Christine Perras, Jessie Cunningham, Tarun Ahuja, Trevor Richter, Christopher Kovacs.
More information:

Abstract:

Osteoporosis is a skeletal disorder characterized by compromised bone strength, predisposing patients to an increased risk of fracture. The postmenopausal form of osteoporosis affects more than 1.5 million Canadians, with prevalence increasing from 6% of women aged 50 to 59 years to more than 40% of women aged 80 years and older. Consequences of sustaining a fracture may be serious and include increased risk of subsequent fractures, hospitalization or institutionalization, decreased quality of life, and premature mortality, with a related burden on the health care system. Antiresorptive agents such as oral bisphosphonates are the standard treatment for postmenopausal osteoporosis, in conjunction with non-pharmacologic measures. Other treatment options include an intravenous bisphosphonate (zoledronic acid), a monoclonal antibody (denosumab), a bone-forming agent (teriparatide), and a selective estrogen receptor modulator (raloxifene). This systematic review was undertaken following a request from provincial drug formularies to evaluate the clinical effectiveness and harms of three of these agents, denosumab, raloxifene, and zoledronic acid, in postmenopausal women with osteoporosis. The evidence gathered is expected to clarify uncertainty regarding these agents and to inform policy-making in the population of interest.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/793582938> # Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis : clinical effectiveness and harms
    a schema:Book, schema:CreativeWork, schema:MediaObject ;
   library:oclcnum "793582938" ;
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/2257495518#Topic/bone_density_conservation_agents_adverse_effects> ; # Bone Density Conservation Agents--adverse effects
   schema:about <http://experiment.worldcat.org/entity/work/data/2257495518#Topic/osteoporosis_postmenopausal_drug_therapy> ; # Osteoporosis, Postmenopausal--drug therapy
   schema:about <http://experiment.worldcat.org/entity/work/data/2257495518#Topic/raloxifene_therapeutic_use> ; # Raloxifene--Therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/2257495518#Topic/bone_density_conservation_agents_therapeutic_use> ; # Bone Density Conservation Agents--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/2257495518#Topic/rank_ligand_antagonists_&_inhibitors> ; # RANK Ligand--antagonists & inhibitors
   schema:about <http://experiment.worldcat.org/entity/work/data/2257495518#Topic/osteoporosis_in_women_chemotherapy> ; # Osteoporosis in women--Chemotherapy
   schema:about <http://dewey.info/class/616.716/e22/> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/2257495518#Topic/raloxifene_hydrochloride_therapeutic_use> ; # Raloxifene Hydrochloride--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/2257495518#Topic/diphosphonates_therapeutic_use> ; # Diphosphonates--therapeutic use
   schema:about <http://experiment.worldcat.org/entity/work/data/2257495518#Topic/osteoporosis_drugs_therapeutic_use> ; # Osteoporosis drugs--Therapeutic use
   schema:author <http://viaf.org/viaf/305937628> ; # Kasandra Gauthier
   schema:bookFormat schema:EBook ;
   schema:contributor <http://viaf.org/viaf/145374402> ; # Canadian Agency for Drugs and Technologies in Health,
   schema:datePublished "2012" ;
   schema:description "Osteoporosis is a skeletal disorder characterized by compromised bone strength, predisposing patients to an increased risk of fracture. The postmenopausal form of osteoporosis affects more than 1.5 million Canadians, with prevalence increasing from 6% of women aged 50 to 59 years to more than 40% of women aged 80 years and older. Consequences of sustaining a fracture may be serious and include increased risk of subsequent fractures, hospitalization or institutionalization, decreased quality of life, and premature mortality, with a related burden on the health care system. Antiresorptive agents such as oral bisphosphonates are the standard treatment for postmenopausal osteoporosis, in conjunction with non-pharmacologic measures. Other treatment options include an intravenous bisphosphonate (zoledronic acid), a monoclonal antibody (denosumab), a bone-forming agent (teriparatide), and a selective estrogen receptor modulator (raloxifene). This systematic review was undertaken following a request from provincial drug formularies to evaluate the clinical effectiveness and harms of three of these agents, denosumab, raloxifene, and zoledronic acid, in postmenopausal women with osteoporosis. The evidence gathered is expected to clarify uncertainty regarding these agents and to inform policy-making in the population of interest."@en ;
   schema:description "Acronyms and abbreviations -- Executive summary -- 1. Context and policy issues -- 2. Research question -- 3. Key message -- 4. Methods -- 5. Results -- 6. Discussion -- 7. Conclusions and implications for decision- or policy-making -- 8. References -- Appendix 1: Literature search strategy -- Appendix 2: Selection of included studies -- Appendix 3: Summary of study characteristics of included studies -- Appendix 4: Summary of relevant patient population and baseline characteristics -- Appendix 5: Critical appraisal of individual studies."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/2257495518> ;
   schema:genre "National government publication"@en ;
   schema:genre "Government publication"@en ;
   schema:genre "Electronic books"@en ;
   schema:inLanguage "en" ;
   schema:isPartOf <http://worldcat.org/issn/1922-8147> ; # Rapid response report (Canadian Agency for Drugs and Technologies in Health)
   schema:name "Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis : clinical effectiveness and harms"@en ;
   schema:productID "793582938" ;
   schema:url <http://www.ncbi.nlm.nih.gov/books/NBK169524/> ;
   schema:url <http://www.deslibris.ca/ID/231799> ;
   schema:url <https://www.ncbi.nlm.nih.gov/books/NBK169524> ;
   schema:url <http://site.ebrary.com/id/10544950> ;
   schema:url <http://public.eblib.com/choice/publicfullrecord.aspx?p=3279203> ;
   schema:url <http://www.cadth.ca/media/pdf/tr0001_Osteoporosis_e.pdf?&utm_source=tr0001&utm_medium=vo2-issue-8&utm_campaign=communique-03-13-12> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/793582938> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/2257495518#Topic/bone_density_conservation_agents_adverse_effects> # Bone Density Conservation Agents--adverse effects
    a schema:Intangible ;
   schema:name "Bone Density Conservation Agents--adverse effects"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2257495518#Topic/bone_density_conservation_agents_therapeutic_use> # Bone Density Conservation Agents--therapeutic use
    a schema:Intangible ;
   schema:name "Bone Density Conservation Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2257495518#Topic/diphosphonates_therapeutic_use> # Diphosphonates--therapeutic use
    a schema:Intangible ;
   schema:name "Diphosphonates--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2257495518#Topic/osteoporosis_postmenopausal_drug_therapy> # Osteoporosis, Postmenopausal--drug therapy
    a schema:Intangible ;
   schema:name "Osteoporosis, Postmenopausal--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2257495518#Topic/raloxifene_hydrochloride_therapeutic_use> # Raloxifene Hydrochloride--therapeutic use
    a schema:Intangible ;
   schema:name "Raloxifene Hydrochloride--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2257495518#Topic/rank_ligand_antagonists_&_inhibitors> # RANK Ligand--antagonists & inhibitors
    a schema:Intangible ;
   schema:name "RANK Ligand--antagonists & inhibitors"@en ;
    .

<http://viaf.org/viaf/145374402> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
   schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://viaf.org/viaf/305937628> # Kasandra Gauthier
    a schema:Person ;
   schema:familyName "Gauthier" ;
   schema:givenName "Kasandra" ;
   schema:name "Kasandra Gauthier" ;
    .

<http://worldcat.org/issn/1922-8147> # Rapid response report (Canadian Agency for Drugs and Technologies in Health)
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/793582938> ; # Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis : clinical effectiveness and harms
   schema:issn "1922-8147" ;
   schema:name "Rapid response report (Canadian Agency for Drugs and Technologies in Health)" ;
   schema:name "Rapid response report : systematic review," ;
    .

<http://www.worldcat.org/title/-/oclc/793582938>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
   schema:about <http://www.worldcat.org/oclc/793582938> ; # Denosumab, raloxifene, and zoledronic acid for the treatment of postmenopausal osteoporosis : clinical effectiveness and harms
   schema:dateModified "2017-12-25" ;
   void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.